Two different tools, two different questions

When a consultant mentions two sets of scores after a cartilage procedure, patients often ask: what are they actually measuring — and do the numbers agree?

The International Knee Documentation Committee Subjective Knee Score — IKDC for short — is an 18-item questionnaire completed by the patient. It covers pain, swelling, stiffness, daily activities, and sport, running from 0 to 100. A score of 100 means no limitation in any of those areas; a result around 80 broadly equates to comfortable everyday life and recreational activity without significant restriction.

The Magnetic Resonance Observation of Cartilage Repair Tissue score — MOCART — is something quite different: a radiologist's reading of an MRI scan. It assesses how well the repair tissue fills the original defect, how it integrates with surrounding healthy cartilage, whether the surface is congruent, and what the tissue signal looks like on imaging. It also runs from 0 to 100, with a result above 80 indicating that more than 80% of the defect has filled with sound border integration.

Think of it this way: the IKDC scores how the knee feels to live in; the MOCART scores what a structural survey of the cartilage shows. They share the same numerical range but ask entirely separate questions — and independent systematic-review evidence confirms that a high score on one does not reliably predict a high score on the other. That is precisely why clinicians use both.

How ChondroFiller works as an injectable scaffold

ChondroFiller is a CE-marked, cell-free collagen type I hydrogel placed into a focal cartilage defect as an outpatient, ultrasound-guided injection — no surgery or general anaesthetic is involved. Because the scaffold contains no cells of its own, it works by creating the right conditions for the patient's biology to take over: the collagen matrix draws progenitor cells in from the surrounding synovium and subchondral bone, a process called acellular matrix-induced chondrogenesis. The hydrogel provides the structure; the patient's own biology does the building.

Ex vivo data published in 2025 recorded a 2.4-fold increase in DNA content within the scaffold by day 14, confirming that active cellular recruitment begins almost immediately after placement. That biological sequence is the reason scores do not peak overnight. Repair tissue matures progressively as cells migrate, differentiate, and remodel the collagen matrix over weeks to months — which is precisely why IKDC improvements continue through the 3-, 6-, and 12-month follow-up windows seen in clinical studies, rather than arriving as a single step change.

In the early weeks, the gel is still stabilising within the defect. A 2024 in vitro biomechanical study found that premature full loading before stable fill is established may increase stress on adjacent cartilage surfaces, which is why weight-bearing is typically restricted until that consolidation is confirmed. Patients can expect progressive functional improvement that mirrors the underlying biology — gradual, measurable, and supported by both structural and patient-reported evidence.

IKDC score changes patients can expect

Going from a baseline IKDC score near 48 to a result close to 80 represents the journey from meaningful daily restriction — pain affecting stairs, disturbing sleep, or ruling out sport — to comfortable everyday life with recreational activity largely restored. That roughly 32-point rise is what two independent peer-reviewed studies have recorded in knee patients treated with ChondroFiller.

Both a 2016 prospective randomised multicentre trial (n=13) and Simeonov's 2024 single-centre cohort (n=17, mean age 31) demonstrated statistically significant IKDC improvements at 3, 6, and 12 months post-procedure (p<0.05). The trajectory follows the scaffold's biology: measurable gains arrive early, build through the first six months, then consolidate. Simeonov found no statistically significant further change between the 6- and 12-month timepoints, indicating that most functional recovery is established within the first year.

The three-year Post-Market Clinical Follow-up data from Jerosch place the mean IKDC at 80.1 — a rise of approximately 32.4 points from a starting point near 48. To calibrate that figure: the Minimal Clinically Important Difference for the IKDC is 16.7 points, defined as the smallest change a patient would actually notice in daily life. A 32-point gain exceeds that threshold more than twofold, meaning patients are not marginally better — they are substantially better by a margin felt across every measured area of the questionnaire: pain frequency, swelling, range of movement, and the ability to participate in recreational activity.

Across published cohorts, some 70–85% of appropriately selected patients achieve lasting, clinically meaningful symptom relief at the 3–5 year mark. Patient selection remains central to that figure: ChondroFiller is indicated for focal defects in an otherwise stable joint, not for generalised or advanced osteoarthritis, and outcomes in unsuitable candidates would not be expected to match this range.

MOCART scores and cartilage maturation on MRI

MRI timing matters more than patients often realise. Because the collagen scaffold takes months to resorb and host progenitor cells take time to consolidate within the defect, a scan at six or eight weeks will typically show lower fill than one taken at twelve months. The MOCART score reflects where repair tissue is in that maturation journey at the moment of scanning — not the eventual destination — so an early result should be read as a progress marker rather than a final verdict.

Published European ChondroFiller knee studies place MOCART scores in the 81.6–84.3 range at one year, a band corresponding to more than 80% defect fill with sound border integration and an acceptably smooth surface contour. Available three-year follow-up data align with that same range rather than showing any structural decline, suggesting the repair tissue remains stable once the scaffold has fully resorbed and mature host-derived cartilage occupies the defect space.

When reading a radiologist's report, the language most directly relevant to the MOCART result includes phrases about completeness of fill — 'complete', 'nearly complete', or 'greater than 50%' — alongside descriptors of how the repair tissue meets the adjacent native cartilage ('intact integration', 'complete') and whether the surface contour is smooth or shows irregularity. These phrases map directly onto the score's principal domains without a patient needing to recalculate a number.

MOCART describes tissue structure, not symptoms. A report confirming complete fill and intact integration says nothing by itself about pain levels or walking capacity — and that distinction shapes how the two scores should be used together, which the following section addresses.

When IKDC and MOCART point in different directions

Good structural fill on MRI does not guarantee good function — and the reverse is equally true. This is not an anomaly or a sign that something has gone wrong; it is a well-documented finding that has been formally examined in peer-reviewed research.

The two scores measure different things. IKDC captures how a patient moves through the world — pain frequency, swelling, capacity for sport, comfort on stairs. MOCART records what a radiologist observes in a scan: fill volume, tissue signal, surface congruence. These constructs are related, but they are not the same, and the evidence confirms they do not track each other reliably.

A 2021 systematic review of knee cartilage patients found no statistically significant association between MOCART scores and IKDC (p=0.9), Lysholm scores (p=0.2), Tegner activity ratings, VAS pain, or revision rates. A 2025 comparative study of 111 patients with 188 post-operative MRIs reached the same conclusion: neither the original MOCART nor MOCART 2.0 correlated significantly with change in patient-reported outcomes overall.

In practical terms this means a patient can score highly on both instruments, or differently on each — and both outcomes are clinically plausible. Someone reporting excellent function may have a less-than-perfect MRI appearance; someone with near-complete defect fill may still experience discomfort that requires further assessment.

Clinicians therefore interpret IKDC and MOCART alongside a physical examination and clinical history rather than as standalone verdicts. Neither number should be read in isolation, and a mismatch between the two prompts further investigation rather than alarm.

Who is likely to benefit and what the evidence still lacks

Patient selection is the starting point for any honest assessment of this pathway. ChondroFiller is designed for focal chondral defects — a discrete, bounded area of cartilage loss — rather than the diffuse joint-wide thinning characteristic of moderate-to-advanced osteoarthritis. Published success rates of 70–85% at three to five years apply specifically to patients selected on defect grade, defect size, and overall joint condition; patients with generalised OA are not suitable candidates.

The evidence base has real limitations worth naming plainly. Both independent knee study designs — the 2016 multicentre trial (n=13) and Simeonov's 2024 cohort (n=17) — involved small patient numbers, and no large-scale randomised controlled trial exists. The multicentre trial also suffered from high dropout in the comparator arm, constraining what can be concluded about head-to-head performance against microfracture. Peer-reviewed five-year knee-specific data have not yet been published; the three-year PMCF data show structural stability, but durability beyond that point remains an open question.

One practical matter carries immediate clinical weight: the post-procedure loading protocol. Biomechanical in-vitro evidence shows the gel does not protect the opposing joint surface under early full cyclic loading, because the material requires time to stabilise within the defect. Weight-bearing restrictions during this period reflect a genuine biomechanical rationale, not precautionary formality.

Against these caveats, the real-world safety record across more than 19,000 cases since 2013 is reassuring: a 0.06% complaint rate and no reported serious adverse events. Small study cohorts sit within that broader safety experience rather than in tension with it.

The honest framing for a patient at decision stage: ChondroFiller has good short-to-medium-term functional evidence for appropriately selected focal defects, a well-established safety profile, and a plausible biological mechanism — but long-term peer-reviewed durability data are still accumulating. Whether the pathway suits a specific knee requires a consultant assessment of defect characteristics and overall joint health. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral; book an assessment at lincolnshireknee.co.uk.

1. [1] Controlled, Randomized Multicenter Study: ChondroFiller Liquid vs Microfracturing for Focal Knee Cartilage Defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Reliability of the MOCART Score: A Systematic Review. (2021). https://doi.org/10.1186/s10195-021-00603-w https://doi.org/10.1186/s10195-021-00603-w
4. [4] Correlation and Comparative Evaluation of MOCART and MOCART 2.0 for Assessing Cartilage Repair. (2025). https://doi.org/10.3390/medicina61040745 https://doi.org/10.3390/medicina61040745
5. [5] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] The MOCART 2.0 Knee Score and Atlas. (2019). https://doi.org/10.1177/1947603519865308 https://doi.org/10.1177/1947603519865308
7. [7] Influence of Cartilage Defects and a Collagen Gel on Integrity of Corresponding Intact Cartilage. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z